BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • May 2023
  • August 2021
  • July 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us

Browsing Tag

Multikine

5 posts
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
BioTech Health X
  • May 31, 2023

Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

  • 3 minute read
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
0 Shares
0
0
0
0
0
0
0
Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head Neck Patients in Phase 3 Trial
BioTech Health X
  • May 31, 2023

Biotech NewsCel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial

  • 3 minute read
Data Shows Significant Overall Survival Benefit for Cancer Patients with Multikine Treatment Regimen Followed by Surgery & Radiotherapy…
0 Shares
0
0
0
0
0
0
0
CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
BioTech Health X
  • May 27, 2023

Biotech NewsCEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

  • 8 minute read
CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…
0 Shares
0
0
0
0
0
0
0
Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
Jak Thomson
  • May 23, 2023

BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

  • 10 minute read
About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused…
0 Shares
0
0
0
0
0
0
0
EF Hutton Initiates Coverage of Cel-Sci CVM with 17 Price Target Ahead of Rumored News
BioTech Health X
  • May 23, 2023

Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News

  • 5 minute read
Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
  • Advanced Chemotherapy Technologies Receives $4 Million NIH Grant to Pursue Pancreatic Cancer Treatment
  • Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
  • Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial
  • Denali Therapeutics Announces Scientific Journal Publication of Preclinical Proof of Concept for Protein Transport Vehicle (PTV)
Recent Comments
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • May 31, 2023
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    • May 31, 2023
    Advanced Chemotherapy Technologies Receives $4 Million NIH Grant to Pursue Pancreatic Cancer Treatment
    Advanced Chemotherapy Technologies Receives 4 Million NIH Grant to Pursue Pancreatic Cancer Treatment
    • May 31, 2023
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    • May 31, 2023
    Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial
    Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head Neck Patients in Phase 3 Trial
    • May 31, 2023
    Denali Therapeutics Announces Scientific Journal Publication of Preclinical Proof of Concept for Protein Transport Vehicle (PTV)
    Denali Therapeutics Announces Scientific Journal Publication of Preclinical Proof of Concept for Protein Transport Vehicle PTV
Recent Posts
  • ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    • May 31, 2023
  • 11/19/21
    • May 30, 2023
  • Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery T Cell Receptors
    Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery & T Cell Receptors
    • May 29, 2023
Categories
  • BioTech CEO Interviews (4)
  • Biotech Info (1)
  • Biotech News (45)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by Code Supply Co.
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us
Back to top